Anal Cancer Market: Global Industry Analysis and Forecast (2024-2030)

Anal Cancer Market size was valued at USD 698 Mn. in 2023 and the total Anal Cancer Market size is expected to grow at a CAGR of 6.4% from 2024 to 2030, reaching nearly USD 1077 Mn. by 2030.

Format : PDF | Report ID : SMR_2052

Anal Cancer Market Overview

Anal cancer is a form of malignancy that occurs rarely and typically initiates in the anus, which is the terminal opening of the rectum. Technological developments in targeted medicines, immunotherapies, and radiation procedures are driving a dynamic shift in the anal cancer market. Historically, the usual course of treatment has been a mix of radiation and chemotherapy, with surgery saved for special circumstances. However, immunotherapies that use the body's immune system and targeted medicines that block particular biochemical pathways are emerging as viable substitutes.

Besides this, other approaches to tumor treatment like radiation therapy involving protons and intensity-modulated radiation therapy (IMRT) are becoming better such that they can focus very effectively on tumors without causing serious side effects. Biomarker research is also gaining more interest especially when it comes to finding out who is sick at what stage and which treatments are specific for their conditions. As always, clinical trials are key when examining newly introduced management measures.

As per SMR analysis, a higher number of Anal Cancer cases were observed in localized (Stage I) anal cancer, followed by regional (Stage II–III) cases, with the fewest cases being accounted for by distant/metastatic (Stage IV) anal cancer, in the US.

Anal Cancer Market

To get more Insights: Request Free Sample Report

Anal Cancer Market Dynamics

Drivers: Increasing Prevalence of Anal Cancer Drives the Global Market

Globally, the incidence of anal cancer has surged dramatically. The global incidence of anal cancer in 2023 was documented to be 58854 cases, as reported by GLOBOCAN. Similarly, the American Cancer Society estimates that the lifetime incidence rate of anal cancer is approximately 1 in 500. Moreover, there has been a documented rising trend in the annual incidence of mortality linked to anal cancer.

There are some people who are more likely than others to get anal cancer because they have certain things that increase their chances. Usually, squamous cell anal cancers are caused by human papillomavirus. All cancer cases across the world can be traced back to the human papillomavirus disease called HPV at about 15%. Approximately 675,500 women and 78,600 men get cancer annually due to HPV infections All these factors are driving the growth of Anal Cancer market.

Ongoing Clinical Trials and Research Creates Tremendous Opportunities

More and more clinical trials and research works are being done for anal cancer that are seeking to ascertain new drugs and treatment methods. A clinical trial began in September 2023 by Kharofa working together with Ride Cincinnati which is a non-profit bicycle organization involved in cancer research and patient treatment. The major end goal of this particular trial would be to reduce the side effects of drugs as well as improve patient outcomes especially in those ones that have been diagnosed with anal cancer, which influencing the Anal Cancer Market.

Increasing Awareness and Screening Programs:

Earlier diagnosis and better outcomes can result from raised awareness drives as well as screening activities. Likely prospects involve entering into partnerships with healthcare givers so as to encourage early detection, informing susceptible communities on preventive aspects and appealing for policy alterations that uphold screening schemes and the right to access health care. These factors fueling the growth of Anal Cancer Market.

Anal Cancer Market Segment Analysis:

Based on Treatment Type, Anal Cancer Market is Divided into Chemotherapy, Surgery, Radiation Therapy Immunotherapy However Chemotherapy treatment significantly used worldwide Chemotherapy treatment involves the use of chemical substances to kill cancer cells. Chemotherapy can be used alone or in combination with other treatments like radiation therapy and immunotherapy. Chemotherapy can cause side effects such as hair loss, nausea, and fatigue.

Anal Cancer Market1

Anal Cancer Market Regional Insights:

The North America region held the largest anal cancer market share due mainly to increased regional cases of anal cancer and significant healthcare spending. Cases of anal cancer are increasing thereby leading to increased medical attention and resources. Its well-developed healthcare infrastructure specifically in America and Canada has seen it become home for modern medical facilities as well as professionals who are able to make accurate diagnoses quickly. An increase in healthcare spending in the area has enabled the provision of intensive medical care with the most up-to-date technologies and access to experimental therapies. This is supported by raising awareness and early diagnosis through various programs, leading to better results of treatment of patients.

Anal Cancer Market2

Anal Cancer Market Competitive Landscape

In November 2023, Eli Lilly, an American pharmaceutical corporation, disclosed its intention to construct a new manufacturing facility in western Germany, representing a substantial investment of 2 billion euros (approximately USD 2.17 billion).
In August 2023, Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. jointly announced that LONSURF (trifluridine/tipiracil) had been granted FDA approval for treating metastatic colorectal cancer (mCRC) in adults. This approval applies to patients who had previously received chemotherapy involving fluoropyrimidine, oxaliplatin, and irinotecan, as well as anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.
June 2023: AstraZeneca and Daiichi Sankyo represented positive results from the clinical study of the DESTINY CRC02 phase trial for Enhertu, comprising effectiveness and safety in patients with previously treated HER-2 positive metastatic colorectal cancer.

Anal Cancer Market Scope

Anal Cancer Market
Market Size in 2023	USD 698 Mn.
Market Size in 2030	USD 1077 Mn.
CAGR (2024-2030)	6.4 %
Historic Data	2018-2022
Base Year	2023
Forecast Period	2024-2030
Segments	By Cancer Type Carcinoma In Situ Squamous Cell Carcinoma Melanoma Adenocarcinoma Basal Cell Carcinoma Others
	By Treatment type Chemotherapy Surgery Radiation Therapy Immunotherapy
	By End User Hospitals and Clinics Research and Academic Institutes Others
Regional Scope	North America- United States, Canada, and Mexico Europe – United Kingdom, France, Germany, Italy, Spain, Sweden, Russia, and Rest of Europe Asia Pacific – China, India, Japan, South Korea, Australia, ASEAN, Rest of APAC Middle East and Africa - South Africa, GCC, Egypt, Rest of the Middle East and Africa South America – Brazil, Argentina, Rest of South America

Anal Cancer Market Key Players

Novartis AG
Sanofi
AstraZeneca plc
Johnson & Johnson
GlaxoSmithKline plc
Pfizer Inc.
Advaxis Inc.
Spectrum Pharmaceuticals, Inc
Merck
Bayer AG
Bristol-Myers Squibb Company
AbbVie Inc.
F. Hoffmann-La Roche Ltd.
Eli Lilly and Company
Atara Biotherapeutics Inc.
Amgen Inc.
Isofol
Tanvex Biopharma
Sebela Pharmaceuticals
Leap Therapeutics
XX Inc

Buy Now

Request For Free sample

Frequently Asked Questions

1. What are the growth drivers for the Anal Cancer Market?

Increasing Prevalence of Anal Cancer Drives the Global Market, Ongoing Trails and research developments are the growth drivers for the Anal Cancer Market.

2. What is restrain of Anal Cancer Market?

Adverse Effects and related diseases are the restrain of Anal Cancer Market.

3. What is the Projected size & growth of Anal Cancer Market?

Anal Cancer Market size was valued at USD 698 Million in 2023 and the total Anal Cancer Market size is expected to grow at a CAGR of 6.4 % from 2024 to 2030, reaching nearly USD 1077 Million by 2030.

4. What Segments are covered in Anal Cancer Market?

Segments are covered based on By Cancer Type, By Treatment Type, By End User.

1.   Research Methodology
1.1   Research Data
1.1.1.   Primary Data
1.1.2.   Secondary Data
1.2.   Market Size Estimation
1.2.1.   Bottom-Up Approach
1.2.2.   Top-Down Approach
1.3.   Market Breakdown and Data Triangulation
1.4.   Research Assumption
2.   Anal Cancer Market Executive Summary
2.1.   Market Overview
2.2.   Market Size (2023) and Forecast (2024 – 2030) and Y-O-Y%
2.3.   Market Size (USD) and Market Share (%) – By Segments and Regions
3.   Global Anal Cancer Market: Competitive Landscape
3.1.   SMR Competition Matrix
3.2.   Key Players Benchmarking
3.2.1.   Company Name
3.2.2.   Headquarter
3.2.3.   Service Segment
3.2.4.   End-user Segment
3.2.5.   Y-O-Y%
3.2.6.   Revenue (2023)
3.2.7.   Profit Margin
3.2.8.   Market Share
3.2.9.   Company Locations
3.3.   Market Structure
3.3.1.   Market Leaders
3.3.2.   Market Followers
3.3.3.   Emerging Players
3.4.   Consolidation of the Market
3.4.1.   Strategic Initiatives and Developments
3.4.2.   Mergers and Acquisitions
3.4.3.   Collaborations and Partnerships
4.   Anal Cancer Market: Dynamics
4.1.   Anal Cancer Market Trends by Region
4.1.1.   North America
4.1.2.   Europe
4.1.3.   Asia Pacific
4.1.4.   Middle East and Africa
4.1.5.   South America
4.2.   Anal Cancer Market Drivers
4.3.   Anal Cancer Market Restraints
4.4.   Anal Cancer Market Opportunities
4.5.   Anal Cancer Market Challenges
4.6.   PORTER’s Five Forces Analysis
4.6.1.   Intensity of the Rivalry
4.6.2.   Threat of New Entrants
4.6.3.   Bargaining Power of Suppliers
4.6.4.   Bargaining Power of Buyers
4.6.5.   Threat of Substitutes
4.7.   PESTLE Analysis
4.7.1.   Political Factors
4.7.2.   Economic Factors
4.7.3.   Social Factors
4.7.4.   Technological Factor
4.7.5.   Legal Factors
4.7.6.   Environmental Factors
4.8.   Technological Roadmap
4.9.   Regulatory Landscape by Region
4.9.1.   North America
4.9.2.   Europe
4.9.3.   Asia Pacific
4.9.4.   Middle East and Africa
4.9.5.   South America
5.   Anal Cancer Market: Global Market Size and Forecast by Segmentation (by Value in USD Million) (2023-2030)
5.1.   Anal Cancer Market Size and Forecast, by Cancer Type (2023-2030)
5.1.1.   Carcinoma In Situ
5.1.2.   Squamous Cell Carcinoma
5.1.3.   Melanoma
5.1.4.   Adenocarcinoma
5.1.5.   Basal Cell Carcinoma
5.1.6.   Others
5.2.   Anal Cancer Market Size and Forecast, by Treatment Type (2023-2030)
5.2.1.   Chemotherapy
5.2.2.   Surgery
5.2.3.   Radiation Therapy
5.2.4.   Immunotherapy
5.3.   Anal Cancer Market Size and Forecast, by End User (2023-2030)
5.3.1.   Hospitals and Clinics
5.3.2.   Research and Academic Institutes
5.3.3.   Others
5.4.   Anal Cancer Market Size and Forecast, by Region (2023-2030)
5.4.1.   North America
5.4.2.   Europe
5.4.3.   Asia Pacific
5.4.4.   Middle East and Africa
5.4.5.   South America
6.   North America Anal Cancer Market Size and Forecast by Segmentation (by Value in USD Million) (2023-2030)
6.1.   North America Anal Cancer Market Size and Forecast, by Cancer Type (2023-2030)
6.1.1.   Carcinoma In Situ
6.1.2.   Squamous Cell Carcinoma
6.1.3.   Melanoma
6.1.4.   Adenocarcinoma
6.1.5.   Basal Cell Carcinoma
6.1.6.   Others
6.2.   North America Anal Cancer Market Size and Forecast, by Treatment Type (2023-2030)
6.2.1.   Chemotherapy
6.2.2.   Surgery
6.2.3.   Radiation Therapy
6.2.4.   Immunotherapy
6.3.   North America Anal Cancer Market Size and Forecast, by End User (2023-2030)
6.3.1.   Hospitals and Clinics
6.3.2.   Research and Academic Institutes
6.3.3.   Others
6.4.   North America Anal Cancer Market Size and Forecast, by Country (2023-2030)
6.4.1.   United States
6.4.2.   Canada
6.4.3.   Mexico
7.   Europe Anal Cancer Market Size and Forecast by Segmentation (by Value in USD Million) (2023-2030)
7.1.   Europe Anal Cancer Market Size and Forecast, by Cancer Type (2023-2030)
7.2.   Europe Anal Cancer Market Size and Forecast, by Treatment Type (2023-2030)
7.3.   Europe Anal Cancer Market Size and Forecast, by End User (2023-2030)
7.4.   Europe Anal Cancer Market Size and Forecast, by Country (2023-2030)
7.4.1.   United Kingdom
7.4.2.   France
7.4.3.   Germany
7.4.4.   Italy
7.4.5.   Spain
7.4.6.   Sweden
7.4.7.   Russia
7.4.8.   Rest of Europe
8.   Asia Pacific Anal Cancer Market Size and Forecast by Segmentation (by Value in USD Million) (2023-2030)
8.1.   Asia Pacific Anal Cancer Market Size and Forecast, by Cancer Type (2023-2030)
8.2.   Asia Pacific Anal Cancer Market Size and Forecast, by Treatment Type (2023-2030)
8.3.   Asia Pacific Anal Cancer Market Size and Forecast, by End User (2023-2030)
8.4.   Asia Pacific Anal Cancer Market Size and Forecast, by Country (2023-2030)
8.4.1.   China
8.4.2.   S Korea
8.4.3.   Japan
8.4.4.   India
8.4.5.   Australia
8.4.6.   ASEAN
8.4.7.   Rest of Asia Pacific
9.   Middle East and Africa Anal Cancer Market Size and Forecast by Segmentation (by Value in USD Million) (2023-2030)
9.1.   Middle East and Africa Anal Cancer Market Size and Forecast, by Cancer Type (2023-2030)
9.2.   Middle East and Africa Anal Cancer Market Size and Forecast, by Treatment Type (2023-2030)
9.3.   Middle East and Africa Anal Cancer Market Size and Forecast, by End User (2023-2030)
9.4.   Middle East and Africa Anal Cancer Market Size and Forecast, by Country (2023-2030)
9.4.1.   South Africa
9.4.2.   GCC
9.4.3.   Egypt
9.4.4.   Rest of ME&A
10.   South America Anal Cancer Market Size and Forecast by Segmentation (by Value in USD Million) (2023-2030)
10.1.   South America Anal Cancer Market Size and Forecast, by Cancer Type (2023-2030)
10.2.   South America Anal Cancer Market Size and Forecast, by Treatment Type (2023-2030)
10.3.   South America Anal Cancer Market Size and Forecast, by End User (2023-2030)
10.4.   South America Anal Cancer Market Size and Forecast, by Country (2023-2030)
10.4.1.   Brazil
10.4.2.   Argentina
10.4.3.   Rest Of South America
11.   Company Profile: Key Players
11.1.   Novartis AG
11.1.1.   Company Overview
11.1.2.   Business Portfolio
11.1.3.   Financial Overview
11.1.3.1.   Total Revenue
11.1.3.2.   Segment Revenue
11.1.3.3.   Regional Revenue
11.1.4.   SWOT Analysis
11.1.5.   Strategic Analysis
11.1.6.   Recent Developments
11.2.   Sanofi
11.3.   AstraZeneca plc
11.4.   Johnson & Johnson
11.5.   GlaxoSmithKline plc
11.6.   Pfizer Inc.
11.7.   Advaxis Inc.
11.8.   Spectrum Pharmaceuticals, Inc
11.9.   Merck
11.10.   Bayer AG
11.11.   Bristol-Myers Squibb Company
11.12.   AbbVie Inc.
11.13.   F. Hoffmann-La Roche Ltd.
11.14.   Eli Lilly and Company
11.15.   Atara Biotherapeutics Inc.
11.16.   Amgen Inc.
11.17.   Isofol
11.18.   Tanvex Biopharma
11.19.   Sebela Pharmaceuticals
11.20.   Leap Therapeutics
11.21.   XX Inc
12.   Key Findings
13.   Analyst Recommendations
13.1.   Strategic Recommendations
13.2.   Future Outlook